Axsome Therapeutics (NASDAQ:AXSM) CEO Herriot Tabuteau Sells 78,703 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 78,703 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $171.28, for a total transaction of $13,480,249.84. Following the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $1,238,183.12. The trade was a 91.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Herriot Tabuteau also recently made the following trade(s):

• On Tuesday, January 6th, Herriot Tabuteau sold 29,450 shares of Axsome Therapeutics stock. The stock was sold at an average price of $172.33, for a total transaction of $5,075,118.50.
• On Wednesday, January 7th, Herriot Tabuteau sold 31,261 shares of Axsome Therapeutics stock. The shares were sold at an average price of $170.38, for a total transaction of $5,326,249.18.
• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The shares were sold at an average price of $148.18, for a total transaction of $1,564,484.44.
• On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The stock was sold at an average price of $144.59, for a total transaction of $7,121,346.68.
• On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The shares were sold at an average price of $146.94, for a total value of $2,962,751.22.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total value of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The stock was sold at an average price of $134.49, for a total value of $2,928,519.75.
• On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The shares were sold at an average price of $132.34, for a total value of $12,136,239.70.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $170.69 on Thursday. The company’s fifty day moving average price is $149.54 and its 200 day moving average price is $127.07. Axsome Therapeutics, Inc. has a 1 year low of $79.19 and a 1 year high of $184.40. The stock has a market capitalization of $8.60 billion, a P/E ratio of -36.55, a P/E/G ratio of 9.06 and a beta of 0.44. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The company had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. The business’s revenue was up 63.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AXSM. GAMMA Investing LLC increased its stake in Axsome Therapeutics by 65.4% in the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after purchasing an additional 106 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Axsome Therapeutics by 42.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 250,513 shares of the company’s stock valued at $30,425,000 after buying an additional 74,885 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of Axsome Therapeutics by 6.6% in the 3rd quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock valued at $175,000 after buying an additional 89 shares in the last quarter. CIBC Private Wealth Group LLC grew its position in shares of Axsome Therapeutics by 5.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 14,375 shares of the company’s stock valued at $1,746,000 after buying an additional 686 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in Axsome Therapeutics during the 3rd quarter worth $524,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright raised 2026 earnings estimates substantially (Q2, Q3, Q4 and FY2026 to $3.72 EPS total) and reiterated a “Buy” rating with a $200 price target — this signals higher expected profitability and gives investors a near-term target above current levels.
• Positive Sentiment: UBS reiterated its Buy rating on AXSM, reinforcing institutional analyst support that can buoy demand for the shares. UBS Sticks to Their Buy Rating for Axsome Therapeutics
• Positive Sentiment: Market commentary highlights two late-2025 FDA developments — acceptance of a supplemental filing for AXS-05 (agitation in Alzheimer’s) and FDA support for an NDA filing for AXS-12 (narcolepsy). Those regulatory moves expand potential indications and revenue runway, and underpin the bullish analyst view. Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
• Neutral Sentiment: Street positioning remains overwhelmingly positive (majority of analysts are Buy) and recent reiterations/price targets suggest upside, but consensus still reflects variability in timing and magnitude of revenue from new indications.
• Negative Sentiment: CEO insider sales — Herriot Tabuteau sold a combined 139,414 shares across Jan. 5–7 for roughly $23.88M in proceeds; after these trades the CEO directly owns 7,229 shares (a ~90%+ reduction in their position). Large, concentrated insider selling can create near‑term selling pressure and raise governance/optics concerns for some investors. SEC Filing — Insider Transactions

Wall Street Analysts Forecast Growth

AXSM has been the topic of a number of research analyst reports. Royal Bank Of Canada lifted their price target on Axsome Therapeutics from $189.00 to $198.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 4th. Guggenheim reaffirmed a “buy” rating and issued a $205.00 target price on shares of Axsome Therapeutics in a research note on Friday, January 2nd. Mizuho set a $217.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. Finally, UBS Group boosted their price objective on shares of Axsome Therapeutics from $163.00 to $248.00 and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $191.88.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.